Shares of Corvus Pharmaceuticals rose after its investigational drug soquelitinib showed positive results in an early-stage trial in atopic dermatitis patients. The stock surged 50% to $12.10 in ...

Nearly 9 in 10 adults and parents of children with plaque psoriasis, atopic dermatitis, and seborrheic dermatitis being ...

It’s been said before and it’s true: a healthy scalp is key to healthy hair. But for those dealing with pesky and sometimes painful scalp conditions like seborrheic dermatitis, that can be easier said ...

Cohort 4 data demonstrated positive safety and efficacy results, including additional clinical benefit observed following ...

Amlitelimab is an investigational anti-OX40 ligand monoclonal antibody designed to normalize the overactive immune response in patients with atopic dermatitis.

Sanofi has announced that its amlitelimab has shown positive results in the treatment of patients 12 years and older with ...

If you’re a person of color, finding the right treatment for atopic dermatitis, a common form of eczema, can be challenging. Even though the disease is more prevalent in Black Americans than white ...

Corvus Pharmaceuticals (NASDAQ:CRVS) shares surged 48% on Tuesday after the company released positive findings from a Phase 1 ...

Experts discuss the unique challenges of managing atopic dermatitis (AD) in pediatric and adolescent patients, emphasizing the strategic use of topical treatments to improve adherence, reduce ...

Experts discuss the importance of balancing effective symptom control with quality of life in managing chronic pediatric atopic dermatitis, emphasizing personalized treatment plans that address both ...

Investing.com -- Corvus Pharmaceuticals (NASDAQ:CRVS) stock surged 48% Tuesday morning following the company’s announcement ...

Reviewed By Steven R. Feldman, MD, PhD, Professor of Dermatology, Pathology and Social Sciences & Health Policy, Wake Forest School of Medicine, Winston-Salem, North Carolina Coping with the symptoms ...